logo
Wall Street buyout barons and fat cat CEOs blamed for the two biggest hospital bankruptcies in decades

Wall Street buyout barons and fat cat CEOs blamed for the two biggest hospital bankruptcies in decades

Daily Mail​3 days ago
Private equity companies are facing scrutiny for the collapse of two major hospital chains that left thousands without medical care.
Prospect Medical Holdings filed for bankruptcy in January, forcing the closure of two hospitals in Pennsylvania.
Another major chain, Steward Health Care, filed for bankruptcy in 2024.
Both companies were owned by large private equity vehicles — Leonard Green & Partners and Cerberus Capital Management, respectively — which extracted millions for their investors between 2011 and 2018.
Probes into the chains' operations found the practice depleted their finances so badly it contributed to their collapse, The Wall Street Journal reported.
Communities affected by both Prospect and Steward's collapses have been forced to pay tens of millions of dollars to bail out their healthcare providers.
The funds have had to come from state and local government as well as non-profit community groups.
Both Steward and Prospect have unpaid property taxes and other unmet bills, forcing some communities to hike property taxes, according to the Journal.
As well as the financial hit, communities across the US have been left without critical healthcare services due to the collapse of the chains.
Prospect operated 16 hospitals and more than 165 clinics across California, Connecticut, Pennsylvania and Rhode Island.
Once an aggressive acquirer of struggling hospitals, it collapsed under mounting debt earlier this year.
As part of its bankruptcy proceedings Steward closed two hospitals in Massachusetts — Carney Hospital in Dorchester and Nashoba Valley Medical Center in Ayer — and sold off a further six.
Steward is now suing its former CEO Ralph de la Torre, claiming he pilfered millions from the hospital chain as it went bankrupt.
Filings previously revealed by The Wall Street Journal showed that after de la Torre took over majority ownership of Steward in 2020, he received personal payments of at least $250 million over the next four years.
He went on to use the money to purchase a $7.2 million 500-acre ranch in Waxahachie, Texas, and a 190-foot, $40 million yacht.
He was also revealed to own a 11,108-square-foot mansion in Dallas, valued at more than $7 million.
Ralph de la Torre's 190-foot $40 million yacht. The former cardiac doctor is said to have received vast sums of money for his role as CEO of Steward
Steward is now alleging that de la Torre and his team of executives defrauded the company of $262 million and wasted a further $1.1 billion on buying up overpriced hospitals in Florida.
The complaint filed last month claims that the catastrophic investments were made to fulfil de la Torre's 'personal desire to build a hospital empire,' a reckless move that involved overpaying about $200 million for the properties.
The most recent filings also claim that de la Torre and other executives paid themselves a $111 million dividend in 2021, despite knowing that Steward was in trouble as early as 2016.
Prospect meanwhile paid out $654 million in dividends and share sales between 2012 and 2018.
This directly led to the company running out of cash, a report by a bipartisan congressional committee found.
After Prospect-owned hospitals Crozer-Chester Medical Center and Taylor Hospital were closed earlier this year, residents have been forced to lean on 911 services for non-emergency care, the Journal reported.
'A lot of people are calling emergency medical services for things for which you'd go to your family physicians,' Shane Wheeler, chief of staff for the Volunteer Medical Services Corps of Lansdale, told the publication.
'We're seeing a high level of uncompensated care.'
Others are seeing more than one-year wait times for doctor's appointments.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trump administration in talks to take 10% stake in Intel, Bloomberg News reports
Trump administration in talks to take 10% stake in Intel, Bloomberg News reports

Reuters

time30 minutes ago

  • Reuters

Trump administration in talks to take 10% stake in Intel, Bloomberg News reports

Aug 18 (Reuters) - The Trump administration is in talks to take a 10% stake in Intel by converting some or all of the struggling company's Chips Act grants into equity, Bloomberg News reported, citing a White House official and other people familiar with the matter. Shares of Intel (INTC.O), opens new tab fell about 3% on Monday, after rallying last week on hopes of U.S. federal support. A 10% stake in the American chipmaker would be worth about $10 billion. Intel has been slated to receive a combined $10.9 billion in Chips Act grants for commercial and military production, and the figure is roughly enough to pay for the government's holding, according to the Bloomberg report on Monday. Intel declined to comment on the report, while the White House did not respond to a request for comment. Reuters could not immediately verify the report. Media reports said last week that the U.S. government may buy a stake in Intel, after a meeting between CEO Lip-Bu Tan and President Donald Trump that was sparked by Trump's demand for the new Intel chief's resignation over his ties to Chinese firms. Federal backing could give Intel more breathing room to revive its loss-making foundry business, analysts have said, but it still suffers from a weak product roadmap and challenges in attracting customers to its new factories. "The fact that the U.S. government is stepping in to save a blue-chip American company likely means that Intel's competitive position was much worse than what anybody feared," said David Wagner, head of equity and portfolio manager at Intel shareholder Aptus Capital Advisors. Wagner added that while he was skeptical about the U.S. government investing taxpayer money into U.S. companies, it was better than having Intel become a state-owned entity. Aptus Capital Advisors holds 80,581 shares of Intel. Trump, who said the meeting with Tan was "very interesting" one, has taken an unprecedented approach to corporate interventions. He has pushed for multibillion-dollar government tie-ups in semiconductors and rare earths, such as a pay-for-play deal with Nvidia (NVDA.O), opens new tab and an arrangement with rare earth producer MP Materials (MP.N), opens new tab to secure critical minerals. The U.S. government has previously taken equity stakes in companies under stress. During the 2007-2009 financial crisis, it took a stake in General Motors (GM.N), opens new tab — later exiting the stake in 2013. Intel last year secured nearly $8 billion in subsidies, the largest outlay under the act, to build new factories in Ohio and other states as former CEO Pat Gelsinger bet on them to restore the company's manufacturing edge. Tan, however, pared back such ambitions, slowing construction in Ohio. He plans to build factories based on demand for the services, which analysts have said could put him at odds with Trump's push to shore up American manufacturing.

Gold prices steady as investors assess Trump–Zelenskiy meeting
Gold prices steady as investors assess Trump–Zelenskiy meeting

Reuters

timean hour ago

  • Reuters

Gold prices steady as investors assess Trump–Zelenskiy meeting

Aug 18 (Reuters) - Gold prices were largely steady on Monday, as investors focused on U.S. President Donald Trump's meeting with Ukrainian and European leaders, and the Federal Reserve's annual symposium in Jackson Hole this week. Spot gold was marginally down at $3,333.32 per ounce at 01:42 p.m. ET (1742 GMT), after hitting its lowest level since August 1 earlier in the session. U.S. gold futures for December delivery settled 0.1% lower at $3,378. The U.S. dollar gained 0.3%, making greenback-priced bullion more expensive for other currency holders. Trump said the U.S. would "help out" Europe in providing security for Ukraine as part of any deal to end Russia's war in Ukraine, as he and President Volodymyr Zelenskiy began a hastily arranged White House meeting to discuss a path to peace. The European leaders will meet with Trump afterwards in the White House's East Room at 3 p.m. EDT (1900 GMT), according to the White House. The meeting between Trump and Zelenskiy follows Trump's meeting with Putin on Friday, where the two leaders agreed to pursue a peace deal without implementing a ceasefire. "There was not much reaction in gold to the Putin-Trump meeting. I think we'll continue in this price range. The next inflection point is the Federal Reserve (conference)," said Marex analyst Edward Meir. Minutes from the U.S. central bank's July policy meeting are due on Wednesday, ahead of the Fed's annual conference in Jackson Hole, Wyoming, scheduled for August 21–23. Fed Chair Jerome Powell is expected to speak at the event. Investors will be watching out for Powell's remarks on the economic outlook. While markets have already priced in a 25 basis point cut, there's an outside chance of a 50 basis point reduction, which could drive gold prices higher, Meir said. Gold tends to perform strongly in environments with low interest rates and heightened uncertainty. Elsewhere, spot silver rose 0.1% at $38.02 per ounce, while platinum fell 0.1% to $1,334.10. Spot palladium gained 1% to $1,122.86 after falling to its lowest level since July 10 earlier in the session.

‘Fat jabs' for cats and dogs coming to a vet near you
‘Fat jabs' for cats and dogs coming to a vet near you

Telegraph

timean hour ago

  • Telegraph

‘Fat jabs' for cats and dogs coming to a vet near you

Weight-loss treatments for pets are being created to help obese animals slim down. Veterinary versions of revolutionary GLP-1 drugs, such as Wegovy and Mounjaro, are being developed and tested by scientists. But while the human medicines are administered by injections once a week, the pet drugs would be delivered via implants. Early stage clinical trials in cats found that small doses of the drug exenatide, which works in a similar way to semaglutide and tirzepatide, is effective at reducing the animals' calorie intake and body weight. A study last year fitted five cats with an experimental subcutaneous implant, known as OKV-119, which released the weight loss chemical into the blood for 84 days. Analysis found four of five cats had a reduction in body mass of at least five per cent. This drug-delivery system trial is now being extended to dogs as part of a partnership between drug companies Okava and Vivani. If the trials are successful, the drugs could be available as early as 2028. 'What owners should expect to see is their pet eating appropriate portions without the previous food obsession – they'll still eat regularly and show interest in meals, just without the excessive begging, scavenging or gulping behaviour,' Michael Klotsman, the Okava chief executive, told The Guardian. He added that the medication should be viewed as an 'additional tool' rather than a first action for overweight dogs. Excess body weight can shorten lives of pets and reduce the quality of their life as well, with increased risk of cancers, arthritis, heart disease and other ailments. Some breeds are more prone to being overweight than others, with labradors among the most fat-prone of dogs. One in four labradors has a genetic fault in the POMC gene, which makes them 25 per cent slower at burning calories. The faulty POMC gene is also seen in two thirds of flat-coated retrievers, data show, and is linked to a heightened risk of obesity and being motivated by food. It is thought that around half of all cats and dogs in the UK are overweight, and scientists advise that owners worried about their pet's weight focus on regular exercise and not overfeeding. Snacks can quickly add up calorie intake and exceed a pet's recommended amount, especially in smaller pets, which need only a small amount of calories a day.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store